Published in PLoS Pathog on April 12, 2012
Mechanisms of immune evasion in leishmaniasis. Adv Appl Microbiol (2013) 1.04
Deception and manipulation: the arms of leishmania, a successful parasite. Front Immunol (2014) 0.93
Regulation of immunity during visceral Leishmania infection. Parasit Vectors (2016) 0.92
Regulatory actions of Toll-like receptor 2 (TLR2) and TLR4 in Leishmania donovani infection in the liver. Infect Immun (2013) 0.85
Crucial and diverse role of the interleukin-33/ST2 axis in infectious diseases. Infect Immun (2015) 0.84
Immunotherapy and Immunochemotherapy in Visceral Leishmaniasis: Promising Treatments for this Neglected Disease. Front Immunol (2014) 0.83
Innate immunity against Leishmania infections. Cell Microbiol (2015) 0.81
Sphingolipid degradation in Leishmania (Leishmania) amazonensis. PLoS Negl Trop Dis (2012) 0.77
Successful Therapy of Murine Visceral Leishmaniasis with Astrakurkurone, a Triterpene Isolated from the Mushroom Astraeus hygrometricus, Involves the Induction of Protective Cell-Mediated Immunity and TLR9. Antimicrob Agents Chemother (2016) 0.76
Co-administration of α-GalCer analog and TLR4 agonist induces robust CD8(+) T-cell responses to PyCS protein and WT-1 antigen and activates memory-like effector NKT cells. Clin Immunol (2016) 0.76
Immune responses against protozoan parasites: a focus on the emerging role of Nod-like receptors. Cell Mol Life Sci (2016) 0.75
Local delivery of the TLR9 ligand, CpG, down-regulates host immune and inflammatory responses, ameliorating established Leishmania (Viannia) panamensis chronic infection. Infect Immun (2017) 0.75
Effects of Invariant NKT Cells on Parasite Infections and Hygiene Hypothesis. J Immunol Res (2016) 0.75
Leishmania infantum Exoproducts Inhibit Human Invariant NKT Cell Expansion and Activation. Front Immunol (2017) 0.75
Toll-like receptors: critical proteins linking innate and acquired immunity. Nat Immunol (2001) 18.80
The biology of NKT cells. Annu Rev Immunol (2007) 14.43
Exogenous and endogenous glycolipid antigens activate NKT cells during microbial infections. Nature (2005) 7.72
Innate immune recognition: mechanisms and pathways. Immunol Rev (2000) 5.15
The regulatory role of Valpha14 NKT cells in innate and acquired immune response. Annu Rev Immunol (2001) 4.91
Identification of an IL-17-producing NK1.1(neg) iNKT cell population involved in airway neutrophilia. J Exp Med (2007) 4.47
Therapeutic targeting of innate immunity with Toll-like receptor agonists and antagonists. Nat Med (2007) 4.39
Failure of pentavalent antimony in visceral leishmaniasis in India: report from the center of the Indian epidemic. Clin Infect Dis (2000) 3.72
CD40 triggering of heterodimeric IL-12 p70 production by dendritic cells in vivo requires a microbial priming signal. Immunity (2000) 3.27
Gangliosides: structure, isolation, and analysis. Methods Enzymol (1982) 3.20
Cutting edge: NKT cells constitutively express IL-23 receptor and RORgammat and rapidly produce IL-17 upon receptor ligation in an IL-6-independent fashion. J Immunol (2008) 2.90
Characterization of the early stages of thymic NKT cell development. J Exp Med (2005) 2.84
Structural determinants of Ricinus communis agglutinin and toxin specificity for oligosaccharides. J Biol Chem (1979) 2.60
IL-4 rapidly produced by V beta 4 V alpha 8 CD4+ T cells instructs Th2 development and susceptibility to Leishmania major in BALB/c mice. Immunity (1997) 2.54
Immunopathogenesis of infection with the visceralizing Leishmania species. Microb Pathog (2005) 2.19
Leishmania species: models of intracellular parasitism. J Cell Sci (1999) 2.13
Use of defined TLR ligands as adjuvants within human vaccines. Immunol Rev (2011) 2.09
Genetically resistant mice lacking MyD88-adapter protein display a high susceptibility to Leishmania major infection associated with a polarized Th2 response. J Immunol (2003) 1.91
MyD88 is essential for clearance of Leishmania major: possible role for lipophosphoglycan and Toll-like receptor 2 signaling. Eur J Immunol (2003) 1.82
Innate invariant NKT cells recognize Mycobacterium tuberculosis-infected macrophages, produce interferon-gamma, and kill intracellular bacteria. PLoS Pathog (2008) 1.81
Toll-like receptor 4 contributes to efficient control of infection with the protozoan parasite Leishmania major. Infect Immun (2004) 1.65
Lipoteichoic acid-stimulated p42/p44 MAPK activation via Toll-like receptor 2 in tracheal smooth muscle cells. Am J Physiol Lung Cell Mol Physiol (2004) 1.64
T helper (h)1/Th2 and Leishmania: paradox rather than paradigm. Immunol Lett (2005) 1.58
NK cell activation in visceral leishmaniasis requires TLR9, myeloid DCs, and IL-12, but is independent of plasmacytoid DCs. J Exp Med (2007) 1.57
TLR9 signaling is essential for the innate NK cell response in murine cutaneous leishmaniasis. Eur J Immunol (2007) 1.46
Cutting edge: crucial role of IL-1 and IL-23 in the innate IL-17 response of peripheral lymph node NK1.1- invariant NKT cells to bacteria. J Immunol (2010) 1.44
RNA interference reveals a role for TLR2 and TLR3 in the recognition of Leishmania donovani promastigotes by interferon-gamma-primed macrophages. Eur J Immunol (2006) 1.41
Clinical and experimental advances in treatment of visceral leishmaniasis. Antimicrob Agents Chemother (2001) 1.39
IL-13 is a susceptibility factor for Leishmania major infection. J Immunol (2000) 1.38
Disruption of the murine interleukin-4 gene inhibits disease progression during Leishmania mexicana infection but does not increase control of Leishmania donovani infection. Infect Immun (1995) 1.35
Endogenous IL-4 is necessary for effective drug therapy against visceral leishmaniasis. Eur J Immunol (2000) 1.32
Understanding the function of CD1-restricted T cells. Nat Immunol (2003) 1.31
Toll-like receptors and leishmaniasis. Infect Immun (2007) 1.27
Differential constitutive and cytokine-modulated expression of human Toll-like receptors in primary neutrophils, monocytes, and macrophages. Int J Med Sci (2008) 1.24
From the Th1/Th2 paradigm towards a Toll-like receptor/T-helper bias. Antimicrob Agents Chemother (2005) 1.23
Cytokine production and killer activity of NK/T-NK cells derived with IL-2, IL-15, or the combination of IL-12 and IL-18. J Immunol (2000) 1.22
Current understandings on the immunology of leishmaniasis and recent developments in prevention and treatment. Br Med Bull (2006) 1.18
Release of IL-12 by dendritic cells activated by TLR ligation is dependent on MyD88 signaling, whereas TRIF signaling is indispensable for TLR synergy. J Leukoc Biol (2010) 1.17
Immune response to leishmania: paradox rather than paradigm. FEMS Immunol Med Microbiol (2007) 1.16
Activation of invariant NKT cells exacerbates experimental visceral leishmaniasis. PLoS Pathog (2008) 1.11
Modification of the Dittmer-Lester reagent for the detection of phospholipid derivatives on thin-layer chromatograms. J Lipid Res (1979) 1.08
Dendritic cell function can be modulated through cooperative actions of TLR ligands and invariant NKT cells. J Immunol (2007) 1.04
Diphenylamine-aniline-phosphoric acid reagent, a versatile spray reagent for revealing glycoconjugates on thin-layer chromatography plates. Anal Biochem (2000) 1.02
Mechanisms of resistance and susceptibility to experimental visceral leishmaniosis: BALB/c mouse versus Syrian hamster model. Vet Res (2011) 1.00
IL-23 modulates CD56+/CD3- NK cell and CD56+/CD3+ NK-like T cell function differentially from IL-12. Int Immunol (2008) 0.99
In vivo antitumor activity of NKT cells activated by the combination of IL-12 and IL-18. J Immunol (2003) 0.98
Genetic background influences immune responses and disease outcome of cutaneous L. mexicana infection in mice. Int Immunol (2005) 0.98
Immature human dendritic cells infected with Leishmania infantum are resistant to NK-mediated cytolysis but are efficiently recognized by NKT cells. J Immunol (2006) 0.97
Glycosphingolipid-blotting: an immunological detection procedure after separation by thin layer chromatography. J Immunol Methods (1984) 0.97
B cells regulate CD40 ligand-induced IL-12 production in antigen-presenting cells (APC) during T cell/APC interactions. J Immunol (1997) 0.97
Infection pattern and immune response in the spleen and liver of BALB/c mice intracardially infected with Leishmania donovani amastigotes. Immunol Lett (2003) 0.90
Visceral Leishmania donovani infection in interleukin-13-/- mice. Infect Immun (2006) 0.87
Immunotherapy as a strategy for treatment of leishmaniasis: a review of the literature. Immunotherapy (2009) 0.86
Induction of interferon-gamma by Taenia crassiceps glycans and Lewis sugars in naive BALB/c spleen and peritoneal exudate cells. Mol Immunol (2006) 0.86
On/off TLR signaling decides proinflammatory or tolerogenic dendritic cell maturation upon CD1d-mediated interaction with invariant NKT cells. J Immunol (2010) 0.84
Genetics and molecular specificity of sialylation of Histophilus somni lipooligosaccharide (LOS) and the effect of LOS sialylation on Toll-like receptor-4 signaling. Vet Microbiol (2011) 0.82
Cystatin cures visceral leishmaniasis by NF-κB-mediated proinflammatory response through co-ordination of TLR/MyD88 signaling with p105-Tpl2-ERK pathway. Eur J Immunol (2010) 0.82
Complete protection against experimental visceral leishmaniasis with complete soluble antigen from attenuated Leishmania donovani promastigotes involves Th1-immunity and down-regulation of IL-10. Eur J Immunol (2009) 0.81
Leishmania donovani glycosphingolipid facilitates antigen presentation by inducing relocation of CD1d into lipid rafts in infected macrophages. Eur J Immunol (2011) 0.81
Leishmania donovani: purification and partial characterization of a glycophosphosphingolipid antigen expressed on promastigote surface. Exp Parasitol (1992) 0.77
Immuno stimulating glycophosphosphingolipid antigen from Leishmania donovani is recognized by visceral leishmaniasis patient sera. Mol Biochem Parasitol (2008) 0.77
Mechanism of amphotericin B resistance in clinical isolates of Leishmania donovani. Antimicrob Agents Chemother (2011) 1.45
Hybrid cell vaccination resolves Leishmania donovani infection by eliciting a strong CD8+ cytotoxic T-lymphocyte response with concomitant suppression of interleukin-10 (IL-10) but not IL-4 or IL-13. Infect Immun (2007) 0.86
In situ immunolocalization and stage-dependent expression of a secretory serine protease in Leishmania donovani and its role as a vaccine candidate. Clin Vaccine Immunol (2010) 0.84
115 kDa serine protease confers sustained protection to visceral leishmaniasis caused by Leishmania donovani via IFN-γ induced down-regulation of TNF-α mediated MMP-9 activity. Immunobiology (2012) 0.83
Complete protection against experimental visceral leishmaniasis with complete soluble antigen from attenuated Leishmania donovani promastigotes involves Th1-immunity and down-regulation of IL-10. Eur J Immunol (2009) 0.81
Leishmania donovani glycosphingolipid facilitates antigen presentation by inducing relocation of CD1d into lipid rafts in infected macrophages. Eur J Immunol (2011) 0.81
TLR-mediated distinct IFN-γ/IL-10 pattern induces protective immunity against murine visceral leishmaniasis. Eur J Immunol (2012) 0.80
In vivo and in vitro antileishmanial activity of Bungarus caeruleus snake venom through alteration of immunomodulatory activity. Exp Parasitol (2013) 0.80
Antiproteolytic and leishmanicidal activity of Coccinia grandis (L.) Voigt leaf extract against Leishmania donovani promastigotes. Indian J Exp Biol (2015) 0.78
Protease inhibitors in potential drug development for Leishmaniasis. Indian J Biochem Biophys (2013) 0.77
Immunolocalization and characterization of two novel proteases in Leishmania donovani: putative roles in host invasion and parasite development. Biochimie (2010) 0.77
Identification, purification, and characterization of a secretory serine protease in an Indian strain of Leishmania donovani. Mol Cell Biochem (2008) 0.77
Immuno stimulating glycophosphosphingolipid antigen from Leishmania donovani is recognized by visceral leishmaniasis patient sera. Mol Biochem Parasitol (2008) 0.77
Evidence of direct interactions between the CC-chemokines CCL3, CCL4 and CCL5 and Leishmania promastigotes. Mol Biochem Parasitol (2006) 0.77
Effect of different serine protease inhibitors in validating the 115 kDa Leishmania donovani secretory serine protease as chemotherapeutic target. Indian J Biochem Biophys (2015) 0.76
UDP-Gal: N-acetylglucosamine beta 1-4 galactosyltransferase expressing live attenuated parasites as vaccine for visceral leishmaniasis. Glycoconj J (2008) 0.76
Leishmania donovani secretory serine protease alters macrophage inflammatory response via COX-2 mediated PGE-2 production. Indian J Biochem Biophys (2014) 0.76
TLR4-mediated activation of MyD88 signaling induces protective immune response and IL-10 down-regulation in Leishmania donovani infection. Indian J Biochem Biophys (2014) 0.75
Asiaticoside induces tumour-necrosis-factor-α-mediated nitric oxide production to cure experimental visceral leishmaniasis caused by antimony-susceptible and -resistant Leishmania donovani strains. J Antimicrob Chemother (2012) 0.75
Bioactivity guided fractionation of Moringa oleifera Lam. flower targeting Leishmania donovani. Indian J Exp Biol (2015) 0.75